FDA Clears Mounjaro to Cut Heart Attack and Stroke Risk
By @sharedot · · 8 pages
- Health
- Diabetes
- FDA
- Pharmaceuticals
The FDA approved Eli Lilly's diabetes drug Mounjaro to reduce cardiovascular risk in high-risk adults with type 2 diabetes, expanding its uses.
What happened
The Food and Drug Administration has approved Eli Lilly's diabetes drug Mounjaro for a new use: cutting the risk of heart attack, stroke, and cardiovascular death in high-risk adults with type 2 diabetes.
The approval, announced by Lilly on August 28, 2026, gives consumers another GLP-1 option for lowering heart-related risk.
In 2024, the FDA approved Novo Nordisk's Wegovy to reduce cardiovascular events in overweight or obese adults without diabetes; Mounjaro's approval extends that logic to the diabetes population.
Why it matters
The approval matters because insurers are more likely to cover GLP-1 drugs when they are prescribed for type 2 diabetes, sleep apnea, or heart attack and stroke risk reduction than for weight loss alone.
USA Today notes that some employers and insurers have been pulling back from covering the drugs for weight loss: a Mercer survey found about 6% of large employers expect to drop GLP-1 weight-loss coverage in 2026, and another 5% plan to drop it in 2027.
A labeled cardiovascular indication could keep Mounjaro on more formularies.
The evidence behind it
The approval rests on a large trial comparing Mounjaro with Lilly's older diabetes drug Trulicity.
FindArticles reports the trial, called SURPASS-CVOT, enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease across 640 sites in 30 countries, following participants for a median of about four years.
Lilly reported tirzepatide had a hazard ratio of 0.92 versus dulaglutide — an estimated 8% lower rate of cardiovascular death, heart attack, or stroke. Multiple outlets, including WBAY, reported the same 8% figure.
The fine print on the data
FindArticles flags an important limit: the confidence interval crossed 1.00, and Lilly said the study met its pre-specified noninferiority objective but did not establish superiority over dulaglutide.
In practical terms, the trial showed Mounjaro was not worse than an established cardiovascular-benefit treatment; it did not prove Mounjaro beats it.
The trial also compared an active drug rather than placebo, so it does not answer how tirzepatide performs against no treatment or in people outside the trial's profile. FindArticles adds that the FDA had not posted a contemporaneous approval notice at publication.
Cost, safety, and access
According to WBAY, GoodRx lists Mounjaro at more than $1,300 without insurance, though a manufacturer copay savings card could bring eligible patients' cost down to as little as $25 per prescription.
Safety labeling carries over: Lilly lists gastrointestinal side effects among common adverse events and warns of pancreatitis, gallbladder problems, severe allergic reactions, and hypoglycemia when combined with certain other diabetes medicines.
FindArticles emphasizes treatment decisions should be individualized and patients should not change therapy based on the announcement alone.
What comes next
Updated FDA prescribing information will define the exact eligible population and treatment details for the new indication.
Drugmakers are racing ahead on next-generation drugs: Lilly said its experimental triple-hormone agonist retatrutide achieved 19% to 28% weight loss, results some patients saw on par with weight-loss surgery, according to USA Today.
Wells Fargo said the GLP-1 pipeline now surpasses cancer drugs as the most valuable category on the horizon, and Goldman Sachs projects global weight-loss drug sales of about $105 billion by 2030. WBAY reports Lilly researchers are testing drugs targeting additional hormones.